Lumoxiti has been approved by the US Food & Drug Administration for relapsed patients, or those with a difficult-to-tackle form of the illness. It is the first new treatment option for the disease in the last two decades.
In clinical trials, 75% of the people taking the drug responded to it. In 30% of cases, Lumoxiti had a “complete durable” effect.
"Today's FDA approval of Lumoxiti represents a significant milestone for people living with hairy cell leukaemia, a rare blood cancer that can result in serious and life-threatening conditions,” said Dave Fredrickson, head of AZ’s oncology unit.
For patients, this approval provides the first FDA-approved medicine for this condition in more than 20 years."